Understanding Liver Fibrosis, NAFLD, and NASH: Causes and Treatment Research

Jump To Section

• Expert Background and Credentials
• Liver Fibrosis Research Focus
• Fatty Liver Disease and NASH
• Academic and Clinical Leadership
• Research Impact and Publications
• Full Transcript

Expert Background and Credentials

Dr. Scott Friedman, MD, is a distinguished liver diseases expert with extensive training. He obtained his medical degree from the Mount Sinai School of Medicine. Dr. Friedman completed his residency in internal medicine at Beth Israel Hospital in Boston. He then pursued a gastroenterology fellowship at the University of California, San Francisco.

Liver Fibrosis Research Focus

Dr. Scott Friedman, MD, has performed pioneering research into the underlying causes of liver fibrosis. His work focuses on the mechanisms of liver scarring in chronic liver disease. This research has direct implications for the reversal of liver fibrosis. Dr. Friedman's investigations provide critical insights for developing new treatments.

Fatty Liver Disease and NASH

The research by Dr. Scott Friedman, MD, is vital for understanding fatty liver disease. His work significantly impacts the treatment of non-alcoholic steatohepatitis (NASH). NASH is a severe form of non-alcoholic fatty liver disease (NAFLD) that can progress to cirrhosis. Dr. Friedman's findings help clarify how these conditions lead to liver damage.

Academic and Clinical Leadership

Dr. Scott Friedman, MD, holds prominent leadership roles at the Icahn School of Medicine at Mount Sinai. He serves as the Dean for Therapeutic Discovery. Dr. Friedman is also the Chief of the Division of Liver Diseases. He is a Professor of Medicine and Professor of Pharmacological Sciences, guiding both research and patient care.

Research Impact and Publications

Dr. Scott Friedman, MD, has received numerous US and international awards for his liver disease research. He has published over 450 articles in peer-reviewed medical journals. Dr. Friedman has also authored multiple books and book chapters on liver diseases. His extensive publication record underscores his major contribution to the field.

Full Transcript

Dr. Anton Titov, MD: Hello from New York! We are with Dr. Scott Friedman, liver diseases expert. We will discuss fatty liver disease, non-alcoholic steatohepatitis, and liver fibrosis.

Dr. Friedman is the Dean for Therapeutic Discovery and Chief of the Division of Liver Diseases at the Icahn School of Medicine at Mount Sinai. He is a Professor of Medicine and Professor of Pharmacological Sciences at Mount Sinai.

Dr. Scott Friedman obtained his MD from Mount Sinai School of Medicine. He did a residency in medicine at Beth Israel Hospital in Boston and a fellowship in gastroenterology at the University of California, San Francisco.

Dr. Friedman was a faculty at UCSF for ten years and a Visiting Professor at the Weizmann Institute of Science in Israel. He then returned to continue his academic and clinical career in New York.

Professor Friedman has performed pioneering research into the underlying causes of liver scarring, known as fibrosis, in chronic liver disease. His work has direct implications for the reversal of liver fibrosis and the treatment of fatty liver disease and other chronic liver diseases.

Professor Friedman has received numerous US and international awards in recognition of his pioneering liver disease research. He published over 450 articles in peer-reviewed medical journals and multiple books and book chapters on liver diseases.

Dr. Anton Titov, MD: Professor Friedman, hello and welcome!

Dr. Scott Friedman, MD: Hello, delighted to be here, Anton. Thank you for including me.